Home Tags Enhertu

Tag: Enhertu

Featured Image: Women and the power to fight breast cancer Courtesy: © 2017. Fotolia. Used with permission.

Trastuzumab deruxtecan Launced in Japan for Patients with HER2 Positive Unresectable...

ADC Review | Editorial Team
This week Daiichi Sankyo announced the launch of trastuzumab deruxtecan (Enhertu®), a HER2 directed antibody-drug conjugate (ADC), in Japan.The newly approved agent is a...
Daiichi Sankyo

Daiichi Sankyo Submits Supplemental New Drug Application for Trastuzumab Deruxtecan in...

Danielle Garcia
In a statement earlier today, Daiichi Sankyo confirmed that it has submitted a supplemental New Drug Application (sNDA) to Japan’s Ministry of Health, Labour...

FDA Approves Trastuzumab Deruxtecan for Unresectable or Metastatic HER2-positive Breast Cancer

Peter Hofland
The U.S. Food and Drug Administration (FDA) has approved fam-trastuzumab deruxtecan-nxki (Enhertu®; Daiichi Sankyo and AstraZeneca)*, a HER2 directed antibody-drug conjugate or ADC, for...
ADC Review, Journal of Antibody-drug Conjugates
ADC Review, Journal of Antibody-drug Conjugates (ISSN 2327-0152) is an international peer-reviewed publication designed to serve the needs of a diverse community of individuals including academia, life sciences, pharma, research, clinicians and physicians. Along with regulatory affairs, we also cover government authorities and representatives from payers to policymakers.

MADE POSSIBLE BY
MabPlex

Latest

Peer Review

© 2013-2020 Sunvalley Communication, LLC. All Rights Reserved.